Drugs / HA35
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06444035 | May → Oct 2024 | chronic ulcer of skin, myofascial pain syndrome | Nakhia Impex LLC | Unknown | No outcome recorded |
| — | NCT06209970 | Dec 2023 → Feb 2024 | — | Nakhia Impex LLC | Completed | No outcome recorded |
| — | NCT05809700 | Jun → Jul 2023 | neuropathy, painful | Dove Medical Press Ltd | Completed | No outcome recorded |
| — | NCT05810649 | Apr → Aug 2023 | chronic ulcer of skin | Nakhia Impex LLC | Completed | No outcome recorded |
| — | NCT05765513 | Feb → Jul 2023 | periodontitis | Dove Medical Press Ltd | Completed | No outcome recorded |
| — | NCT05756595 | Jul 2020 → Dec 2022 | herpes zoster | Dove Medical Press Ltd | Completed | No outcome recorded |
| — | NCT05764226 | Jul 2020 → Dec 2022 | chronic ulcer of skin | Nakhia Impex LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HA35 | “In this study, the tissue-permeable 35 kDa HA fragment HA35 was freshly manufactured by mixing hyaluronidase PH20 injectable solution (H31022111) and high-molecular-weight HA...” NCT05810649 ↗6“the HA fragment HA35, with an average molecular weight of 35 kDa, was produced” NCT05809700 ↗ |
| Known as | 35 kDa B-HA | “METHODS: We elaborated on the production process, bioactivity assay, efficacy analyses, and safety evaluation of an injectable novel HA fragment with an average molecular...” PMID 36686276 ↗ Jan 2023 |
| Known as | B-HA | “Anti-Inflammatory Effects of the 35kDa Hyaluronic Acid Fragment (B-HA/HA35).” PMID 36686276 ↗ Jan 20231“HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability” NCT06209970 ↗ |
| Known as | Bioactive HA | “HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability” NCT06209970 ↗ |
| Modality | Other / unclassified | “injectable novel HA fragment with an average molecular weight of 35 kDa (35 kDa B-HA)” PMID 36686276 ↗ Jan 2023 |
| Route | Subcutaneous | “was injected into the tissue under the heath skin immediately surrounding the chronic wounds” NCT05764226 ↗ |
| Target | CD44 | “35 kDa B-HA induced human erythrocyte aggregation (rouleaux formation) and accelerated erythrocyte sedimentation rates through the CD44 receptor.” PMID 36686276 ↗ Jan 2023 |